Form 4: Spruce Biosciences Director Acquires Stock Options

Percival Barretto-Ko, a director of Spruce Biosciences, acquired stock options for 30,000 shares on May 22, 2024.

Summary

• On May 22, 2024, Percival Barretto-Ko, a director of Spruce Biosciences, acquired stock options for 30,000 shares of common stock.
• The exercise price of these options is $0.7511 per share.
• The options vest on the first anniversary of the grant date or fully vest at the company's 2025 annual stockholder meeting, subject to continuous service.
• The options will also vest in full upon a Change in Control as defined in the 2020 Equity Incentive Plan.
• The options expire on May 21, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is neither overtly positive nor negative.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in biotech companies like Spruce Biosciences.
• Comparable companies such as BioMarin Pharmaceutical and Sarepta Therapeutics also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms to incentivize long-term performance and retention.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates